GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (STU:BT1) » Definitions » Notes Receivable

Biosenic (STU:BT1) Notes Receivable : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biosenic Notes Receivable?

Biosenic's Notes Receivable for the quarter that ended in Jun. 2023 was €0.00 Mil.


Biosenic Notes Receivable Historical Data

The historical data trend for Biosenic's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Notes Receivable Chart

Biosenic Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biosenic Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosenic Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Biosenic Notes Receivable Related Terms

Thank you for viewing the detailed overview of Biosenic's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosenic (STU:BT1) Business Description

Traded in Other Exchanges
Address
Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, Gosselies, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (STU:BT1) Headlines

No Headlines